{
  "trial_id": "NCT03894696",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "18 years and older",
      "label": "met"
    },
    {
      "criterion": "Chronic Hepatitis C infection",
      "label": "met"
    },
    {
      "criterion": "Naive patients who will start a 12-week DAA therapy",
      "label": "met"
    },
    {
      "criterion": "Acceptance to share in study",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Receiving antipsychotic",
      "label": "not_met"
    },
    {
      "criterion": "Previous failure of DAA agents",
      "label": "unknown"
    },
    {
      "criterion": "Significant life-threatening diseases",
      "label": "unknown"
    },
    {
      "criterion": "HCV related liver cirrhosis",
      "label": "not_met"
    },
    {
      "criterion": "Non HCV related liver disease",
      "label": "not_met"
    }
  ],
  "notes": "55-year-old man with chronic hepatitis C infection, on IFN and direct antiviral drugs for 6 months. No evidence of other significant medical conditions.",
  "_meta": {
    "topic_id": "64",
    "trial_id": "NCT03894696",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}